CinCor Pharma, Inc.
CinCor Pharma, Inc.
Share · US17240Y1091 · CINC (XNAS)
Overview
No Price
n/a
1 day
-
1 week
-
1 month
-
3 months
-
6 months
-
Year to date
-
1 year
-
2 years
-
3 years
-
4 years
-
5 years
-
10 years
-
20 years
-
Max
-
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
5
2
0
0
Share Float & Liquidity
Free Float 40,92 %
Shares Float 17,91 M
Shares Outstanding 43,76 M
Company Profile for CinCor Pharma, Inc. Share
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Company Data

Name CinCor Pharma, Inc.
Company CinCor Pharma, Inc.
Symbol CINC
Website https://www.cincor.com
Primary Exchange XNAS NASDAQ
ISIN US17240Y1091
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Marc M. P. de Garidel
Market Capitalization 1 Mrd.
Country United States of America
Currency USD
Employees 0,0 T
Address 200 Clarendon Street, 02116 Boston
IPO Date 2022-01-07

Ticker Symbols

Name Symbol
NASDAQ CINC
More Shares
Investors who hold CinCor Pharma, Inc. also have the following shares in their portfolio:
3DM Digital Manufacturing Ltd.
3DM Digital Manufacturing Ltd. Share
SYDNEY A.FIN 23/33
SYDNEY A.FIN 23/33 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025